Safety, pharmacodynamics, and pharmacokinetics of P2X3 receptor antagonist eliapixant (BAY 1817080) in healthy subjects: Double-blind randomized study

This double-blind, randomized, placebo-controlled study examined the safety and tolerability of ascending repeated doses of eliapixant in 47 healthy adult male volunteers. As part of the study, subjects underwent ATP cough challenge testing prior to and after 13 days of treatment, with cough frequency monitored using the Vitalograph VitaloJAK cough recorder.